Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + sabin inactivated poliovirus vaccine
- Development stage
- Unknown
- Lead developer
- Wuhan Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This quadrivalent combination vaccine is designed to provide active immunity against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis. Developed by the Wuhan Institute of Biological Products, it is notable for being the first combination vaccine in China to utilize inactivated poliovirus strains derived from Sabin strains (sIPV) rather than the traditional Salk strains. The vaccine contains diphtheria and tetanus toxoids to neutralize bacterial toxins, acellular pertussis antigens (typically pertussis toxoid and filamentous hemagglutinin) to protect against *Bordetella pertussis*, and inactivated poliovirus types 1, 2, and 3 to prevent polio infection. It is primarily indicated for the primary immunization and booster series in infants and young children, offering a more convenient dosing schedule by combining four essential pediatric vaccines into a single injection.
- Other names
- DTaP-sIPV vaccineAdsorbed Diphtheria, Tetanus, Acellular Pertussis and Sabin Strain Inactivated Poliovirus Combined Vaccine
02
Targets
PRN (Pertactin)FIM2/FIM3 (Fimbriae types 2 and 3)Diphtheria toxinFHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + sabin inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + sabin inactivated poliovirus vaccine.